HSKA - VolitionRx stock rises 7% on license deal with Heska for Nu.Q Vet cancer screening test
VolitionRx (NYSE:VNRX) will get $10M upfront from Heska (NASDAQ:HSKA) in exchange for exclusive worldwide rights to sell VolitionRx's Nu.Q Vet Cancer screening test at the point of care for companion animals. Volition will also receive up to $18M based on the achievement of near/mid-term milestones. The agreement grants Heska exclusive rights to commercialize the Nu.Q for canine cancer screening and monitoring at the point of care. It also enables Heska to access a wider test menu for companion animals, including feline cancer. In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q Vet Cancer Screening Test in kit format for companion animals, through Heska's network of central reference laboratories. Volition's Nu.Q test will operate on Heska's proprietary Element i+ Immunodiagnostic Analyzer, a point of care platform. VNRX +7.38% pre-market to $3.20
For further details see:
VolitionRx stock rises 7% on license deal with Heska for Nu.Q Vet cancer screening test